Save the Antibiotic Xenleta as a Last Resort

October 2019

Xenleta (zen-LEH-tah, lefamulin) will be the first oral and IV med in a new class of "pleuromutilin" antibiotics.

Xenleta is approved for community-acquired pneumonia. It will be touted as an option for resistant infections due to its unique mechanism.

But Xenleta doesn't seem more effective than other antibiotics.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscription Options

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Influenza Share the Latest Advice About 2019-2020 Influenza Immunizations
E-Cigarettes Emphasize Risks of Vaping and Help Kids and Teens Stop
Medicare Be Familiar With Changes Coming to Medicare Part D in 2020
Anticoagulants Help Manage Direct Oral Anticoagulants Around Surgery
Pediatrics Weigh Options for Managing Type 2 Diabetes in Kids
Contraceptives Don't Jump to the New Progestin-Only Oral Contraceptive, Slynd (Drospirenone)
Pharmacy Practice Demystify the Ins and Outs of Compression Stockings
Vaccines Know When to Discuss HPV Vaccination With Adults Over Age 26
Antibiotics Save the Antibiotic Xenleta as a Last Resort
Immunosuppressives Stay Alert for Safety Issues With Janus Kinase Inhibitors (Xeljanz, etc)
Irritable Bowel Syndrome Watch for Zelnorm's Return for Irritable Bowel Syndrome With Constipation